{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:33:02Z","timestamp":1780565582400,"version":"3.54.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.tube.2020.101924","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T02:07:59Z","timestamp":1585620479000},"page":"101924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preclinical models to optimize treatment of tuberculous meningitis \u2013 A systematic review"],"prefix":"10.1016","volume":"122","author":[{"given":"Carlijn H.C.","family":"Litjens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey H.M.","family":"te Brake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2020.101924_bib1","series-title":"Global tuberculosis report 2019","year":"2019"},{"key":"10.1016\/j.tube.2020.101924_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tube.2020.101924_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldv003","article-title":"Tuberculous meningitis: advances in diagnosis and treatment","volume":"113","author":"Torok","year":"2015","journal-title":"Br Med Bull"},{"key":"10.1016\/j.tube.2020.101924_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00042-07","article-title":"Central nervous system tuberculosis: pathogenesis and clinical aspects","volume":"21","author":"Rock","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tube.2020.101924_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12858","article-title":"Mycobacteria employ two different mechanisms to cross the blood-brain barrier","volume":"20","author":"van Leeuwen","year":"2018","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.tube.2020.101924_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","article-title":"Tuberculous meningitis: a roadmap for advancing basic and translational research","volume":"19","author":"Jain","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.tube.2020.101924_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/156652409787581655","article-title":"Pathogenesis of central nervous system tuberculosis","volume":"9","author":"Be","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.tube.2020.101924_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0044-2017","article-title":"Central nervous system tuberculosis","volume":"5","author":"Leonard","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.tube.2020.101924_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17512433.2019.1552831","article-title":"Intensified antibiotic treatment of tuberculosis meningitis","volume":"12","author":"Cresswell","year":"2019","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.tube.2020.101924_bib10","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1474-4422(13)70168-6","article-title":"Tuberculous meningitis: more questions, still too few answers","volume":"12","author":"Thwaites","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tube.2020.101924_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-pharmtox-010617-052438","article-title":"The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: unraveling the black box","volume":"58","author":"Te Brake","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.tube.2020.101924_bib13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.tube.2020.101924_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2020.101924_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11940-018-0490-9","article-title":"Treatment of tuberculous meningitis and its complications in adults","volume":"20","author":"Davis","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.tube.2020.101924_bib16","first-page":"798764","article-title":"Tuberculous meningitis: diagnosis and treatment overview","volume":"2011","author":"Marx","year":"2011","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.tube.2020.101924_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib18","series-title":"Biopharmaceutics and clincal pharmacokinetics","author":"Gibaldi","year":"1991"},{"key":"10.1016\/j.tube.2020.101924_bib19","first-page":"87","article-title":"Streptomycin and PAS in experimental tuberculosis of Guinea pigs infected intracerebrally with virulent tubercle bacilli","volume":"64","author":"Steenken","year":"1951","journal-title":"Am Rev Tubercul"},{"key":"10.1016\/j.tube.2020.101924_bib20","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/515327","article-title":"A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-Associated death","volume":"177","author":"Tsenova","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.46.6.1887-1895.2002","article-title":"Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis","volume":"46","author":"Tsenova","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib22","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejps.2013.01.017","article-title":"Effect of repeated dosing on rifampin exposure in BALB\/c mice","volume":"49","author":"Hosagrahara","year":"2013","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.tube.2020.101924_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"de Steenwinkel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkl128","article-title":"Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model","volume":"57","author":"Pandey","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/iep.12191","article-title":"Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis","volume":"97","author":"Majeed","year":"2016","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.tube.2020.101924_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijantimicag.2017.08.020","article-title":"Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model","volume":"51","author":"Baijnath","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2020.101924_bib29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib30","doi-asserted-by":"crossref","first-page":"e01014","DOI":"10.1128\/AAC.01014-18","article-title":"Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis","volume":"62","author":"Dian","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0965","article-title":"Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis","volume":"10","author":"Tucker","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tube.2020.101924_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2020.101924_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00913-19","article-title":"Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans","volume":"63","author":"Tucker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jiac.2014.05.008","article-title":"Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides","volume":"20","author":"Cabellos","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib36","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/AAC.00367-09","article-title":"Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii","volume":"54","author":"Pachon-Ibanez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib38","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1128\/AAC.01067-15","article-title":"Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: association with biochemical and immunological parameters","volume":"59","author":"Medellin-Garibay","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkv394","article-title":"Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial","volume":"71","author":"Saktiawati","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/AAC.38.5.1186","article-title":"Rifampin for therapy of experimental pneumococcal meningitis in rabbits","volume":"38","author":"Nau","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/140.3.287","article-title":"Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes","volume":"140","author":"Scheld","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib42","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.37.8.1630","article-title":"Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis","volume":"37","author":"Friedland","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2003.07.015","article-title":"Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis","volume":"23","author":"Lee","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2020.101924_bib44","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.38.6.1320","article-title":"Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis","volume":"38","author":"Paris","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1385\/NCC:2:3:325","article-title":"Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis","volume":"2","author":"Djukic","year":"2005","journal-title":"Neurocritical Care"},{"key":"10.1016\/j.tube.2020.101924_bib46","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.45.11.3092-3097.2001","article-title":"Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis","volume":"45","author":"Rodriguez-Cerrato","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib47","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/605576","article-title":"Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis","volume":"49","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2020.101924_bib51","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1128\/AAC.42.7.1706","article-title":"Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits","volume":"42","author":"Ostergaard","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.42.6.1397","article-title":"Moxifloxacin in the therapy of experimental pneumococcal meningitis","volume":"42","author":"Schmidt","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib53","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1128\/AAC.47.8.2487-2491.2003","article-title":"Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro","volume":"47","author":"Kuhn","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/47.5.611","article-title":"Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model","volume":"47","author":"Destache","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00343-17","article-title":"Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients","volume":"61","author":"Van't Boveneind-Vrubleuskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2020.101924_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/AAC.39.3.593","article-title":"Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits","volume":"39","author":"Nau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s10096-003-1016-1","article-title":"Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis","volume":"22","author":"Cottagnoud","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib59","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib60","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/00365548.2011.582140","article-title":"Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics","volume":"43","author":"Viaggi","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/AAC.00515-06","article-title":"Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains","volume":"51","author":"Beer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0009-9236(99)80175-1","article-title":"Penetration of rifabutin (R) into cerebrospinal fluid (CSF) of ventriculostomy patients","volume":"65","author":"Garey","year":"1999","journal-title":"Am Soc Clin Pharmacol Therapeut."},{"issue":"Suppl 1","key":"10.1016\/j.tube.2020.101924_bib63","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000239577","article-title":"Rifabutin for experimental pneumococcal meningitis","volume":"43","author":"Schmidt","year":"1997","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tube.2020.101924_bib65","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/AAC.33.6.933","article-title":"Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis","volume":"33","author":"Pioget","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.tube.2020.101924_bib66","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1007\/BF01661286","article-title":"Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis","volume":"14","author":"Stahl","year":"1986","journal-title":"Infection"},{"key":"10.1016\/j.tube.2020.101924_bib67","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.38.8.1849","article-title":"Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin","volume":"38","author":"Nau","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.31.6.899","article-title":"Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis","volume":"31","author":"Wolff","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2020.101924_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/joc.2010.22.1.17","article-title":"Linezolid penetration into cerebrospinal fluid and brain tissue","volume":"22","author":"Tsona","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/46.6.981","article-title":"Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model","volume":"46","author":"Cottagnoud","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib72","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13054-016-1523-y","article-title":"Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study","volume":"20","author":"Blassmann","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.tube.2020.101924_bib73","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jac\/dkm325","article-title":"Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation","volume":"60","author":"Lodise","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib74","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.wneu.2016.11.040","article-title":"Evaluation of meropenem penetration into cerebrospinal fluid in patients with meningitis after neurosurgery","volume":"98","author":"Zhang","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.tube.2020.101924_bib75","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/AAC.42.8.2012","article-title":"Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy","volume":"42","author":"Nau","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/322633","article-title":"Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid","volume":"33","author":"Maniu","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/32.4.627","article-title":"Clarithromycin lacks bactericidal activity in cerebrospinal fluid in experimental pneumococcal meningitis","volume":"32","author":"Schmidt","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib78","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tube.2012.07.003","article-title":"Comprehensive analysis of methods used for the evaluation of compounds against","volume":"92","author":"Franzblau","year":"2012","journal-title":"Mycobacterium tuberculosis. Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2020.101924_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/17460441.2015.1049529","article-title":"Animal models in tuberculosis research - where is the beef?","volume":"10","author":"Myllymaki","year":"2015","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/j.tube.2020.101924_bib80","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/ijmr.IJMR_554_18","article-title":"Animal models of tuberculosis: lesson learnt","volume":"147","author":"Singh","year":"2018","journal-title":"Indian J Med Res"},{"issue":"Suppl 3","key":"10.1016\/j.tube.2020.101924_bib81","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/infdis\/jiv183","article-title":"Nonclinical models for antituberculosis drug development: a landscape analysis","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s12276-018-0094-1","article-title":"The wide utility of rabbits as models of human diseases","volume":"50","author":"Esteves","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.tube.2020.101924_bib83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jir786","article-title":"Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions","volume":"205","author":"Harper","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib84","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/CMR.00012-08","article-title":"Animal models of Streptococcus pneumoniae disease","volume":"21","author":"Chiavolini","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tube.2020.101924_bib85","first-page":"5","article-title":"The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy","volume":"53","author":"Grosset","year":"1978","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.tube.2020.101924_bib86","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/ajrccm\/140.5.1189","article-title":"Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide","volume":"140","author":"Lecoeur","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2020.101924_bib87","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib88","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib89","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","article-title":"Drug absorption, distribution, metabolism and excretion considerations in critically ill adults","volume":"9","author":"Roberts","year":"2013","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.tube.2020.101924_bib90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciw757","article-title":"Standardized methods for enhanced quality and comparability of tuberculous meningitis studies","volume":"64","author":"Marais","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2020.101924_bib91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10928-013-9306-4","article-title":"Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications","volume":"40","author":"Shannon","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.tube.2020.101924_bib92","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.42.10.2626","article-title":"Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space","volume":"42","author":"Mindermann","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2020.101924_bib93","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1208\/s12248-017-0050-3","article-title":"Microdialysis: the key to physiologically based model prediction of human CNS target site concentrations","volume":"19","author":"Yamamoto","year":"2017","journal-title":"Aaps j"},{"key":"10.1016\/j.tube.2020.101924_bib94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib95","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","article-title":"Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis","volume":"170","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2020.101924_bib96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1183\/16000617.0085-2015","article-title":"The role of moxifloxacin in tuberculosis therapy","volume":"25","author":"Gillespie","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.tube.2020.101924_bib97","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jama.296.14.1731","article-title":"Translation of research evidence from animals to humans","volume":"296","author":"Hackam","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tube.2020.101924_bib98","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12967-018-1678-1","article-title":"Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail","volume":"16","author":"Pound","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.tube.2020.101924_bib99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.tube.2020.101924_bib100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.tube.2020.101924_bib101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.tube.2020.101924_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007117","article-title":"Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis","volume":"15","author":"Verscheijden","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.tube.2020.101924_bib103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/neu.2017.5588","article-title":"Combining brain microdialysis and translational pharmacokinetic modeling to predict drug concentrations in pediatric severe traumatic brain injury: the next step toward evidence-based pharmacotherapy?","volume":"36","author":"Ketharanathan","year":"2019","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.tube.2020.101924_bib104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/psp4.12414","article-title":"Physiologically-based pharmacokinetic modeling of fluconazole using plasma and cerebrospinal fluid samples from preterm and term infants","volume":"8","author":"Gerhart","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.tube.2020.101924_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ460","article-title":"The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens","volume":"61","author":"Chilukuri","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979220300913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979220300913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:44:21Z","timestamp":1761468261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979220300913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":105,"alternative-id":["S1472979220300913"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2020.101924","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical models to optimize treatment of tuberculous meningitis \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2020.101924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101924"}}